Progenity Progresses its Drug Delivery System Clinical Device Performance Studies
March 10, 2022 09:00 ET
|
Progenity, Inc.
Clinical Device Performance Study in Healthy Volunteers Demonstrated Accurate Localization and Delivery A Clinical Device Performance Study in Patients with Ulcerative Colitis is Now Recruiting SAN...
Progenity Announces Acceptance of Three Abstracts at Digestive Disease Week 2022
February 28, 2022 09:00 ET
|
Progenity, Inc.
SAN DIEGO, Feb. 28, 2022 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company innovating in the field of oral biotherapeutics for gastrointestinal health and beyond, today...
Progenity Shares Two Poster Presentations on Treatment of Gastrointestinal Disorders at ECCO’22
February 22, 2022 09:00 ET
|
Progenity, Inc.
SAN DIEGO, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company innovating in the field of oral biotherapeutics for gastrointestinal health and beyond, today...
Progenity Shares Oral Presentation on Treatment of Gastrointestinal Disorders at 34th Belgian Week of Gastroenterology
February 16, 2022 09:00 ET
|
Progenity, Inc.
SAN DIEGO, Feb. 16, 2022 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company innovating in the field of oral biotherapeutics for gastrointestinal health and beyond, today...
Progenity Strengthens Intellectual Property for Single-Molecule Detection Technology with Additional Patent
January 25, 2022 16:05 ET
|
Progenity, Inc.
SAN DIEGO, Jan. 25, 2022 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), an innovative biotechnology company, today announced the award of another new patent related to its single-molecule...
Progenity Announces Oral Presentation on Treatment of Gastrointestinal Disorders at 34th Belgian Week of Gastroenterology
January 11, 2022 06:30 ET
|
Progenity, Inc.
SAN DIEGO, Jan. 11, 2022 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company innovating in the field of oral biotherapeutics for gastrointestinal health and beyond, today...
Progenity Announces Acceptance of Two Abstracts on Treatment of Gastrointestinal Disorders at ECCO’22
January 05, 2022 06:30 ET
|
Progenity, Inc.
SAN DIEGO, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company innovating in the field of oral biotherapeutics for gastrointestinal health and beyond, today...
Progenity to Participate in the H.C. Wainwright BIOCONNECT Virtual Conference
January 03, 2022 06:30 ET
|
Progenity, Inc.
SAN DIEGO, Jan. 03, 2022 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company innovating in the field of oral biotherapeutics for gastrointestinal health and beyond, today...
Progenity Completes Exit from Laboratory Business with Sale of Affiliate Lab
December 20, 2021 16:05 ET
|
Progenity, Inc.
SAN DIEGO, Dec. 20, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company innovating in the field of oral biotherapeutics for gastrointestinal health and beyond, today...
Progenity Announces New Patent for Single-Molecule Detection Technology
December 02, 2021 06:30 ET
|
Progenity, Inc.
SAN DIEGO, Dec. 02, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company innovating in the fields of gastrointestinal health and oral biotherapeutics, today announced a...